Synthesis and Antidiabetic Assessment of New Coumarin-Disubstituted Benzene Conjugates: An In Silico-In Virto Study

Abstract

Even with the significant advancements in medical and therapeutical fields, finding efficient anti-diabetic and anti-oxidative entities is of high significance in the recent era. New coumarin-disubstituted benzene conjugates were prepared to evaluate their antidiabetic and antioxidative effects. The prepared conjugates (MT0-MT7) were characterized utilizing various analytical techniques, including FTIR, UV-Vis, 1H-NMR, and 13C-NMR. Also, the drug-likeness properties of conjugates were assessed in-silico. The antidiabetic effect of the prepared conjugates was estimated in-vitro based on their inhibitory impact on porcine α-amylase and yeast α-glucosidase enzymes; whereas their antioxidative effect was appraised in-vitro based on their snaring impact on hydroxide and DPPH radicals. The findings of evaluating these effects demonstrated that the MT2 and MT3 conjugates had a prominent antidiabetic effect related to the standard. In addition, the MT0 conjugate showed a distinct antioxidative effect comparable to that of the standard. Thus, MT2, MT3, and MT0 conjugates could be used as scaffolds to develop a new class of antidiabetic and antioxidative entities. Moreover, the in-silico analysis revealed that the majority of the prepared conjugates had convenient drug-likeness properties for the oral drug-delivery system.